Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15192197 | 0.82 | ALDH1A1 (0.46) | MAPTALDH1A1LMNADDB1CRBN | |
| SCHEMBL18383140 | 0.82 | ALDH1A1 (0.46) | MAPTALDH1A1LMNADDB1CRBN | |
| SCHEMBL16794183 | 0.82 | ALDH1A1 (0.46) | MAPTALDH1A1LMNADDB1CRBN | |
| SCHEMBL28835193 | 0.81 | CYP2C19 (0.34) | MAPTALDH1A1LMNAGAACYP2C9 | |
| SCHEMBL16423801 | 0.81 | ALDH1A1 (0.47) | MAPTALDH1A1LMNADDB1CRBN | |
| SCHEMBL16985509 | 0.80 | ALDH1A1 (0.45) | MAPTALDH1A1LMNADDB1CRBN | |
| SCHEMBL1557896 | 0.80 | ALDH1A1 (0.45) | MAPTALDH1A1LMNADDB1CRBN | |
| SCHEMBL26341561 | 0.80 | ALDH1A1 (0.45) | MAPTALDH1A1LMNADDB1CRBN | |
| SCHEMBL16053292 | 0.80 | ALDH1A1 (0.45) | MAPTALDH1A1LMNADDB1CRBN | |
| SCHEMBL1558660 | 0.79 | DDB1 (0.52) | MAPTALDH1A1LMNADDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4635570-A2 | PYRIMIDIN-2-YLAMINO-1H-PYRAZOLS AS LRRK2 INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Denali Therapeutics Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-3998261-B1 | PYRIMIDIN-2-YLAMINO-1H-PYRAZOLS AS LRRK2 INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | DENALI THERAPEUTICS INC (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20250034119-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. | 2025-01-30 | — | — | US | disclosed |
| US-11834439-B2 | Compounds, compositions, and methods | DENALI THERAPEUTICS INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230227436-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-11591316-B2 | Compounds, compositions, and methods | DENALI THERAPEUTICS INC. (US) | 2023-02-28 | — | — | US | disclosed |
| EP-3998261-A1 | PYRIMIDIN-2-YLAMINO-1H-PYRAZOLS AS LRRK2 INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Denali Therapeutics Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| US-20220135546-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-05-05 | — | — | US | disclosed |
| CN-114315819-A | Pyrimidin-2-ylamino-1H-pyrazoles as LRRK2 inhibitors for the treatment of neurodegenerative disorders | 戴纳立制药公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-109311857-B | Pyrimidin-2-ylamino-1H-pyrazoles as LRRK2 inhibitors for the treatment of neurodegenerative disorders | 戴纳立制药公司 | 2021-11-12 | — | — | CN | disclosed |
| US-10590114-B2 | Compounds, compositions, and methods | Denali Therapautics Inc. (US) | 2020-03-17 | — | — | US | disclosed |
| EP-3472153-A1 | PYRIMIDIN-2-YLAMINO-1H-PYRAZOLS AS LRRK2 INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Denali Therapeutics Inc. (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20180208582-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2018-07-26 | — | — | US | disclosed |
| US-9932325-B2 | Compounds, compositions, and methods | DENALI THERAPEUTICS INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20180051009-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. | 2018-02-22 | — | — | US | disclosed |
| WO-2017218843-A1 | PYRIMIDIN-2-YLAMINO-1H-PYRAZOLS AS LRRK2 INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | DENALI THERAPEUTICS INC. (US) | 2017-12-21 | — | — | WO | disclosed |
| US-20170362206-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170015668-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| US-20170015668-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| WO-2015113452-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362206-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | LRRK2, SNCA, PARK7 | MAPT 7/4885ALDH1A1 4177/4885LMNA 1507/4885 |
| US-20180208582-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | LRRK2, SNCA, PARK7 | MAPT 7/4885ALDH1A1 4177/4885LMNA 1507/4885 |
| US-20250034119-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | LRRK2, SNCA, PARK7 | MAPT 7/4885ALDH1A1 4177/4885LMNA 1507/4885 |
| US-10590114-B2 | Compounds, compositions, and methods | LRRK2, SNCA, PARK7 | MAPT 7/4885ALDH1A1 4177/4885LMNA 1507/4885 |
| US-20230227436-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | LRRK2, SNCA, PARK7 | MAPT 7/4885ALDH1A1 4177/4885LMNA 1507/4885 |
| US-11591316-B2 | Compounds, compositions, and methods | LRRK2, SNCA, PARK7 | MAPT 7/4885ALDH1A1 4177/4885LMNA 1507/4885 |
| US-11834439-B2 | Compounds, compositions, and methods | LRRK2, SNCA, PARK7 | MAPT 7/4885ALDH1A1 4177/4885LMNA 1507/4885 |
| US-20220135546-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | LRRK2, SNCA, PARK7 | MAPT 7/4885ALDH1A1 4177/4885LMNA 1507/4885 |
| US-20180051009-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | LRRK2, SNCA, PARK7 | MAPT 7/4885ALDH1A1 4177/4885LMNA 1507/4885 |
| US-20170015668-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | MAPT 6/4885ALDH1A1 3795/4885LMNA 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.